COVID-19 Infection and Nanomedicine Applications for Development of Vaccines and Therapeutics: An Overview and Future Perspectives Based on Polymersomes

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 2021 Feb 5

PMID 33545157

Citations 12

Authors

Mohammad A I Al-Hatamleh

Mamon M Hatmal

Walhan Alshaer

Engku Nur Syafirah E A Rahman

Manali Haniti Mohd-Zahid

Dina M Alhaj-Qasem

Chan Yean Yean

Iskandar Z Alias

Juhana Jaafar

Khalid Ferji

Jean-Luc Six

Vuk Uskokovic

Hiroshi Yabu

Rohimah Mohamud

Affiliations

Soon will be listed here.

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which emerged in December 2019 and caused the coronavirus disease 2019 (COVID-19) pandemic, took the world by surprise with an unprecedented public health emergency. Since this pandemic began, extraordinary efforts have been made by scientists to understand the pathogenesis of COVID-19, and to fight the infection by providing various preventive, diagnostic and treatment opportunities based on either novel hypotheses or past experiences. Despite all the achievements, COVID-19 continues to be an accelerating health threat with no specifically approved vaccine or therapy. This review highlights the recent advances in COVID-19 infection, with a particular emphasis on nanomedicine applications that can help in the development of effective vaccines or therapeutics against COVID-19. A novel future perspective has been proposed in this review based on utilizing polymersome nano-objects for effectively suppressing the cytokine storm, which may reduce the severity of COVID-19 infection.

Citing Articles

A Glance on Nanovaccine: A Potential Approach for Disease Prevention.

Garg A, Agrawal R, Chopra H, Singh T, Chaudhary R, Tankara A Curr Pharm Biotechnol. 2023; 25(11):1406-1418.

PMID: 37861010 DOI: 10.2174/0113892010254221231006100659.

The application of nanomedicine in clinical settings.

Zhao Q, Cheng N, Sun X, Yan L, Li W Front Bioeng Biotechnol. 2023; 11:1219054.

PMID: 37441195 PMC: 10335748. DOI: 10.3389/fbioe.2023.1219054.

Recent Developments in Oral Delivery of Vaccines Using Nanocarriers.

Zafar A, Arshad R, Rehman A, Ahmed N, Akhtar H Vaccines (Basel). 2023; 11(2).

PMID: 36851367 PMC: 9964829. DOI: 10.3390/vaccines11020490.

Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India.

Majumder M, Singh K, Johnson W, Rajasundaram A, Gupta S, Gaur U J Multidiscip Healthc. 2023; 16:161-174.

PMID: 36700174 PMC: 9869700. DOI: 10.2147/JMDH.S390364.

Quality by Design Approach in Liposomal Formulations: Robust Product Development.

Alshaer W, Nsairat H, Lafi Z, Hourani O, Al-Kadash A, Esawi E Molecules. 2023; 28(1).

PMID: 36615205 PMC: 9822211. DOI: 10.3390/molecules28010010.

References

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Graham R, Baric R . Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol. 2009; 84(7):3134-46. PMC: 2838128. DOI: 10.1128/JVI.01394-09. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Rabaan A, Al-Ahmed S, Haque S, Sah R, Tiwari R, Singh Malik Y . SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med. 2020; 28(2):174-184. View

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L . Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020; 221(11):1762-1769. PMC: 7184346. DOI: 10.1093/infdis/jiaa150. View

Vlahos R, Stambas J, Selemidis S . Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy. Trends Pharmacol Sci. 2011; 33(1):3-8. DOI: 10.1016/j.tips.2011.09.001. View

De Gusseme B, Sintubin L, Baert L, Thibo E, Hennebel T, Vermeulen G . Biogenic silver for disinfection of water contaminated with viruses. Appl Environ Microbiol. 2009; 76(4):1082-7. PMC: 2820954. DOI: 10.1128/AEM.02433-09. View

10.

Cotten M, Watson S, Zumla A, Makhdoom H, Palser A, Ong S . Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio. 2014; 5(1). PMC: 3944817. DOI: 10.1128/mBio.01062-13. View

11.

Ye S, Shao K, Li Z, Guo N, Zuo Y, Li Q . Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and Charge Matter. ACS Appl Mater Interfaces. 2015; 7(38):21571-9. DOI: 10.1021/acsami.5b06876. View

12.

Atal S, Fatima Z . IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. Pharmaceut Med. 2020; 34(4):223-231. PMC: 7292936. DOI: 10.1007/s40290-020-00342-z. View

13.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

14.

Lagunas-Rangel F . Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol. 2020; 92(10):1733-1734. PMC: 7228336. DOI: 10.1002/jmv.25819. View

15.

Sekimukai H, Iwata-Yoshikawa N, Fukushi S, Tani H, Kataoka M, Suzuki T . Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol Immunol. 2019; 64(1):33-51. PMC: 7168429. DOI: 10.1111/1348-0421.12754. View

16.

Warnes S, Little Z, Keevil C . Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials. mBio. 2015; 6(6):e01697-15. PMC: 4659470. DOI: 10.1128/mBio.01697-15. View

17.

Hoffmann M, Kleine-Weber H, Pohlmann S . A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020; 78(4):779-784.e5. PMC: 7194065. DOI: 10.1016/j.molcel.2020.04.022. View

18.

Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang Y . Moderate mutation rate in the SARS coronavirus genome and its implications. BMC Evol Biol. 2004; 4:21. PMC: 446188. DOI: 10.1186/1471-2148-4-21. View

19.

Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R . Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2017; 15(1):93-114. DOI: 10.1080/17425247.2017.1360863. View

20.

Svegliati S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G . Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem. 2005; 280(43):36474-82. DOI: 10.1074/jbc.M502851200. View